Where I see patients (1)
My reviews
4.9
Selected research
-
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Journal for immunotherapy of cancer
-
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
European journal of cancer (Oxford, England : 1990)
-
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Circulation research
Clinical trials
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...
Recruiting
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without ...
DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-9900